ElectroCore Concludes Enrollment In COVID-19 Study Evaluating Vagus Nerve Stimulation

by Vandana Singh, Benzinga Editor

February 24, 2021 9:39 AM | 1 min read | Make a Comment

ElectroCore Inc (NASDAQ: ECOR) and the Hospital Clínico Universitario de Valencia in Spain have completed the enrollment in the SAVIOR-1 study. This study was supported in part by electroCore.
The randomized, controlled study evaluates the effect of non-invasive electrical vagus nerve stimulation (nVNS) on respiratory symptoms due to COVID-19.
In July last year, gammaCore SapphireTM CV (the nVNS) received emergency use authorization from the FDA to treat patients with known or suspected COVID-19 who are experiencing an exacerbation of asthma-related dyspnea and reduced airflow.
Price Action: ECOR increased 10.2% at $2.325 on the last check Wednesday.

Posted In: Biotech News Penny Stocks Health Care FDA General Covid-19

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.